SHILPAMED

- India Ratings and Research (Fitch Group) upgraded Shilpa Medicare Ltd's bank facilities to 'IND AA-/Stable/IND A1+' from 'IND A+/Positive/IND A1'. - Its subsidiary, Shilpa Pharma Lifesciences Ltd, also received upgrades for its bank facilities; one non-convertible debenture rating was withdrawn.

The provided PDF document is blank, and no content or financial data could be extracted for analysis.

- Shilpa Biologicals Pvt Ltd (a wholly-owned subsidiary of Shilpa Medicare) entered a co-development and supply agreement with Orion Corporation, Finland.- The agreement is for an intravenous (IV) Nivolumab biosimilar for the European market, targeting a ~USD4.1 billion market (2025 sales in Europe).- Shilpa Biologicals will lead product development and serve as the exclusive long-term commercial manufacturer and supplier.- Shilpa is entitled to receive development and regulatory milestone payments, in addition to supply revenue.

- Intimation of Closure of Trading Window for designated persons. - Effective from July 01, 2026, until 48 hours after declaration of un-audited Financial Results for the quarter ended June 30, 2026. - Board Meeting date for considering these results will be communicated in due course.

- Shilpa Biologicals Pvt. Ltd. (subsidiary) settled a legal dispute with Sartorius Stedim India Pvt. Ltd. for ₹9,00,00,000. - The original claim by Sartorius was for ₹20,13,47,308 plus interest. - The settlement was executed on June 23, 2026.

- Shilpa Biologicals Private Ltd, a material subsidiary of Shilpa Medicare Ltd, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility. - The facility is fully operational, designed to meet global regulatory standards including US FDA and EMA, and is undergoing GMP qualification protocols. - This positions Shilpa as one of India's few companies offering fully integrated, end-to-end ADC Drug Substance development and manufacturing, leveraging its expertise in high potency compound manufacturing.

- Shilpa Medicare Limited declared the results of the postal ballot conducted from May 24, 2026, to June 22, 2026. - The Special Resolution for shifting the Company's Registered Office from one state to another and altering the Situation Clause of the Memorandum of Association was passed with 99.99% votes in favor.